SOX11 as a minimal residual disease marker for Mantle cell lymphoma

Leuk Res. 2014 Aug;38(8):918-24. doi: 10.1016/j.leukres.2014.04.007. Epub 2014 Apr 28.

Abstract

Recent studies have identified SOX11 as a novel diagnostic marker for mantle cell lymphoma (MCL). We quantified SOX11 by a truly mRNA specific qPCR assay in longitudinal peripheral blood samples from 20 patients and evidenced a close relationship of SOX11 expression and clinical status of the patients. In eight patient courses we validated the expression of SOX11 using t(11;14) and demonstrated positive correlation of SOX11 and t(11;14) levels. To the best of our knowledge this is the first report stating that quantification of SOX11 can be used as an minimal residual disease marker equal to the key translocation t(11;14) in MCL.

Keywords: MCL; MRD; Mantle cell lymphoma; Minimal residual disease; SOX11; qPCR; t(11 ;14).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor* / genetics
  • Biomarkers, Tumor* / metabolism
  • Case-Control Studies
  • Chromosomes, Human, Pair 11
  • Chromosomes, Human, Pair 14
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lymphoma, Mantle-Cell / diagnosis*
  • Lymphoma, Mantle-Cell / genetics
  • Lymphoma, Mantle-Cell / pathology
  • Male
  • Middle Aged
  • Monitoring, Physiologic / methods
  • Neoplasm Staging
  • Neoplasm, Residual
  • SOXC Transcription Factors / physiology*
  • Translocation, Genetic

Substances

  • Biomarkers, Tumor
  • SOX11 protein, human
  • SOXC Transcription Factors